Stroke remains a leading cause of death and a significant contributor to the global disease burden, with over 840,000 affected annually in the EU. This research project aims to improve the management of ischemic non-cardioembolic stroke and transient ischemic attack (TIA) using genotype-guided therapy. Current treatment faces challenges: individual genetic differences influence the effectiveness and safety of antiplatelet and statin medications, yet this variability is not considered in standard care. We will conduct a multicentre, randomised controlled trial to evaluate the efficacy and safety of genotype-guided antiplatelet and statin therapies compared to standard-of-care. The trial will enroll 2,250 patients from Finland, Sweden, Denmark, and Spain, with major adverse cardiovascular events as the primary endpoint. In addition, the project will leverage biobank data and samples from the clinical trial to discover biomarkers predicting the response to drugs used by patients with a stroke or TIA. The project also aims to standardise the reporting and integration of pharmacogenomic test results into electronic health records, informed by surveys of current practices and expert consultations. This research will fill critical knowledge gaps and aims to establish genotype-guided therapy as a new standard in stroke management, with the potential to significantly reduce cardiovascular events and improve patient outcomes. By incorporating a wide range of stakeholders, including a patient organisation, clinical decision support company, and healthcare professionals, the project ensures alignment with societal needs, enhancing the translational impact of personalised medicine in stroke care.

The consortium is still under contract negotiations and changes may occur.